^Back To Top
As you know well, Russia has its own procedures for registration of new medicines. One of those national features is registration clinical studies. Every drug product to be registered in Russia should pass local clinical study for its safety and efficacy (under GCP), unless its efficacy and safety had already been studied in multinational clinical study with participation of at least two centers in Russia.
are not required only for very limited groups of medicines like locally confirmed orphan drugs (by separate regulatory procedure according to last amendment to the Drug Law in Russia since July 2015) or generic products having their full registered analogs on the Russian market for more than 20 years.
require extensive clinical study program that includes local phase I, phase II and limited phase III (the latter two phases can be combined into one clinical study in some cases).
imply either conduction of a bioequivalence clinical study on limited number of healthy volunteers (in some cases – patients) or therapeutic equivalence study depending on drug formulation and Russian MoH guidelines for bioequivalence studies.
are typical: Clinical Study Protocol, Case Report Form template (CRF), Investigator Brochure, Patient information leaflet with Patient consent form as well as Life and Health Insurance for subjects in Russia should be prepared in Russian language according to MoH official guidelines and National GCP standard.
And for any clinical study project one should get optimal balance between official Russian regulatory requirements, specifics and possibilities of the clinical centers and patients on the one hand, and your business focus, priorities and market forecast, on the other.